CRISPR Therapeutics AG - Common Shares (CRSP) stock analysis
CRSP · CRISPR Therapeutics AG - Common Shares
Latest recorded price: USD 40.37
Sector and industry: Healthcare · Biotechnology
Fiscal 2025 figures: revenue growth 43.1%, free cash flow margin -9,855.5%, ROIC -222.3%. The model flags 2 risk signals for this company (2 high severity).
Similar companies in Healthcare
- Cytokinetics, Incorporated (CYTK)
- Denali Therapeutics Inc. - Common Stock (DNLI)
- Dianthus Therapeutics, Inc. (DNTH)
- Exelixis, Inc. - Common Stock (EXEL)
- Fortrea Holdings Inc. - Common Stock (FTRE)
- Halozyme Therapeutics, Inc. (HALO)
- Harmony Biosciences Holdings, Inc. - Common Stock (HRMY)
- ImmunityBio, Inc. (IBRX)